atrasentan has been researched along with Uterine Cervical Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagnato, A; Cirilli, A; Flamini, S; Muller, A; Padley, R; Salani, D; Simeone, P; Venuti, A | 1 |
| Bagnato, A; Cirilli, A; Muller, A; Natali, PG; Nicotra, MR; Salani, D; Simeone, P; Venuti, A | 1 |
| Bagnato, A; Cirilli, A; Muller, A; Simeone, P; Venuti, A | 1 |
3 other study(ies) available for atrasentan and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma.
Topics: Atrasentan; Cell Division; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Papillomaviridae; Peptides, Cyclic; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Cell Division; Drug Synergism; Endothelin Receptor Antagonists; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2002 |
Targeting endothelin receptor type A in human cervical carcinoma cells.
Topics: Antineoplastic Agents; Atrasentan; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Female; Human papillomavirus 16; Humans; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Uterine Cervical Neoplasms | 2004 |